VIARTIS

 

PARKINSON'S DISEASE NEWS

 

 

 

 

 

 

FEBRUARY 2017

 

18th February 2017 - New research

VIRTUAL REALITY AIDS PARKINSON'S DISEASE

 CLICK HERE FOR A PRINTABLE OR WHITE BACKGROUND VERSION OF THIS ARTICLE

Virtual reality (VR) technology has been proposed as a new means of rehabilitating people with Parkinson's Disease that has added value over that of physiotherapy. It potentially optimises motor learning in a safe environment, and by replicating real-life scenarios could help improve functional activities of daily living.

Virtual reality (VR) means experiencing things through computers that don't really exist. It is a believable, and interactive 3D computer-created world that you can explore so that you feel you really are there, both mentally and physically. For more information go to : Virtual Reality

Most of the studies intended to improve motor function using commercially available devices were compared with the use of physiotherapy. The interventions lasted for between 4 and 12 weeks. In comparison to physiotherapy, Virtual Reality may lead to a moderate improvement in step and stride length. Virtual Reality and physiotherapy may have similar effects on gait, balance, and quality of life.

However, the authors concluded that there was low-quality evidence of a positive effect of short-term Virtual Reality exercise on step and stride length.

Reference : The Cochrane Database of Systematic Reviews [2016] 12 : CD010760 (K.Dock, E.M.Bekkers, V.Van den Bergh, P.Ginis, L.Rochester, J.M.Hausdorff, A.Mirelman, A. Nieuwboer) Complete abstract In order to refer to this article on its own click here

 

12th February 2017 - News release

L-DOPA INHALER IMPROVES PARKINSON'S DISEASE

 CLICK HERE FOR A PRINTABLE OR WHITE BACKGROUND VERSION OF THIS ARTICLE

The L-dopa inhaler CVT-301 significantly improved Parkinson's Disease symptoms in clinical trials. CVT-301 utilizes ARCUS® for inhaled therapeutics. CVT-301 is designed to deliver a precise dose of a dry powder formulation of L-dopa. Inhaled treatments enter the body through the lungs and then reach the brain far more quickly, by bypassing the digestive system. For more information go to dementia : Arcus

A Phase 3 clinical trial of patients who received CVT-301 in addition to their oral carbidopa/levodopa showed a significant improvement in motor function in people with Parkinson's Disease experiencing OFF periods. Two doses of were assessed - 84 mg and 60 mg (equivalent to 50 mg and 35 mg fine-particle doses). Out of 339 patients, only 6 taking 60mg, and only 2 taking 84mg reported serious adverse effects. The safety profile of CVT-301 was consistent with the Phase IIb clinical trial.

In a previous study the effect of the L-dopa inhaler was around 10 minutes, which is far quicker than the effect of L-dopa when it is taken orally. This would enable the widespread additional use of the L-dopa inhaler for when a quicker effect is required. Acorda said it will file an NDA with the FDA (the U.S. medicines authority) by the end of the second quarter, and a marketing authorisation application with the European Medicines Agency by the end of 2017, pending additional data analyses.  News release : News release   In order to refer to this article on its own click here

 

4th February 2017 - New book

THE COMPREHENSIVE GUIDE TO PARKINSON'S DISEASE

 CLICK HERE FOR A PRINTABLE OR WHITE BACKGROUND VERSION OF THIS ARTICLE

The Comprehensive Guide to Parkinson's Disease, which is fully referenced, and over 800 pages long, is the most comprehensive book concerning Parkinson's Disease ever written. It includes the history of Parkinson 's Disease, famous people with Parkinson's Disease, the first complete biochemisty of Parkinson's Disease, its cytology and cytological effects, anatomy and anatomical effects, physiology and physiological effects, symptoms (of every system in the body), diagnosis methods (observational, technological, chemical), biochemical causes, all of the toxic causes, all of the genetic causes, all of the pharmacological causes, all the other medical disorders that can cause Parkinson's Disease symptoms, its treatments (biochemical, pharmacological, surgical, natural, exercise methods, technological methods), including all those treatments that exist and all those treatments presently being developed, Parkinson's Disease organisations, Parkinson's Disease web sites, and books on Parkinson's Disease nursing.

SECTION 1 HISTORY OF PARKINSON'S DISEASE : Chapter 1 (The history of Parkinson's Disease - includes descriptions of it in ancient India, ancient China, the Bible, ancient Greece, ancient Rome, in medieval history, and during the 16th, 17th, 18th and recent centuries), Chapter 2 (Famous people with Parkinson's Disease)

SECTION 2 PREVALENCE OF PARKINSON'S DISEASE : Chapter 3 (Prevalence of Parkinson's Disease - the world's highest prevalence, the world's lowest prevalence, prevalence rates by country, incidence rates by country, age distribution, gender differences, and occupational differences)

SECTION 3 BIOCHEMISTRY OF PARKINSON'S DISEASE : Chapter 4 (Dopamine biosynthesis), Chapter 5 (Coenzyme biosynthesis), Chapter 6 (Iron metabolism), Chapter 7 (Zinc metabolism), Chapter 8 (Manganese metabolism), Chapter 9 (Dopamine receptors), Chapter 10 (G proteins), Chapter 11 (Dopamine receptor phosphoprotein)


SECTION 4 CYTOLOGY OF PARKINSON'S DISEASE : Chapter 12 (Dopaminergic neurons), Chapter 13 (Cytological effects - superoxide anion, neuromelanin formation, iron accumulation, the accumulation of alpha-synuclein, and the formation of Lewy bodies)

SECTION 5 ANATOMY OF PARKINSON'S DISEASE : Chapter 14 (Dopaminergic neuronal groups), Chapter 15 (Anatomical effects - on each system in the body)

SECTION 6 PHYSIOLOGY OF PARKINSON'S DISEASE : Chapter 16 (Dopaminergic pathways), Chapter 17 (Physiological effects - on each system in the body)

SECTION 7 SYMPTOMS OF PARKINSON'S DISEASE (symptoms, prevalence, causes of symptoms) : Chapter 18 (Primary symptoms), Chapter 19 (Symptom progression), Chapter 20 (Muscular system), Chapter 21 (Nervous system), Chapter 22 (Alimentary system), Chapter 23 (Urinary system), Chapter 24 (Cardiovascular system), Chapter 25 (Respiratory system), Chapter 26 (Skeletal system), Chapter 27 (Integumentary system), Chapter 28 (Sensory system), Chapter 29 (Endocrine system), Chapter 30 (Reproductive system), Chapter 31 (Immune system)

SECTION 8 DIAGNOSIS OF PARKINSON'S DISEASE : Chapter 32 (Observational methods), Chapter 33 (Technological methods), Chapter 34 (Chemical methods)

SECTION 9 CAUSES OF PARKINSON'S DISEASE : Chapter 35 (Biochemical causes), Chapter 36 (Toxic causes - the chemistry, common sources, means of toxicity, symptoms of each of the toxic causes), Chapter 37 (Genetic causes - the gene, chromosome, biochemical function, type of inheritance, symptoms, prevalence, genetic tests for each of the 40 known genetic causes), Chapter 38 (Pharmacological causes - their pharmacology, adverse effects, causes of symptoms of all the pharmacological causes), Chapter 39 (Medical causes - the pathophysiology, symptoms, causes of symptoms of all the medical disorders that can cause Parkinson's Disease symptoms)

SECTION 10 TREATMENTS OF PARKINSON'S DISEASE (their pharmacology, biochemistry, efficacy, adverse effects) : Chapter 40 (Biochemical treatment), Chapter 41 (L-dopa), Chapter 42 (Dopamine agonists), Chapter 43 (MAO inhibitors), Chapter 44 (COMT inhibitors), Chapter 45 (Anti-cholinergics), Chapter 46 (Non-dopaminergic), Chapter 47 (Surgical treatments), Chapter 48 (Natural treatments), Chapter 49 (Exercise methods), Chapter 50 (Technological methods)

APPENDIX : Appendix 1 (Parkinson's Disease organisations), Appendix 2 (Parkinson's Disease web sites), Appendix 3 (Parkinson's Disease nursing books)  CLICK HERE FOR MORE DETAILS

                                                                   

  GO TO JANUARY 2017  

  

  GO TO CURRENT NEWS  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 
©2006-2017 Viartis
 
MAIL@VIARTIS.NET